Ion AmpliSeq™ technology delivers simple and fast library construction for targeted sequencing of specific human genes or genomic regions. Based on ultrahigh-multiplex PCR, Ion AmpliSeq™ technology requires as little as 10 ng of input DNA per reaction to target sets of genes, including SNPs, CNVs, gene fusions, and indels, making sequencing of FFPE samples routine on the Ion PGM™ System.
Alternative target selection methods are lengthy and complex and require large amounts (100s of nanograms) of DNA, making them impractical to routinely sequence DNA or RNA from the formalin-fixed, paraffin-embedded (FFPE) tissues commonly used in clinical cancer research, drug, and companion diagnostic development.
Because Ion AmpliSeq™ technology can amplify hundreds of biomarker targets in a single reaction, the Oncomine® Cancer Research Panel can comprehensively analyze hundreds of the most referenced oncology biomarkers using just 3 primer pools. This not only enables a fast and easy workflow, but also helps ensure that important, actionable—but less prevalent— cancer variants are not missed.
With the power of Ion AmpliSeq™ technology, the Oncomine® Cancer Research Panel can become your universal test for oncology clinical trials and companion diagnostic development.
Discuss the Oncomine® Cancer Research Panel with member of our clinical development team.